Allogeneic hematopoietic cell transplantation (HCT) is an established therapy for a broad range of hematologic malignancies and other disorders. A major limitation of allogeneic HCT Is graft vs host disease (GVHD) caused by alloimmune lymphocytes of the donor recognizing host antigens. GVHD can be characterized as a robust, dysregulated immune response resulting in tissue destruction and ultimately mortality in the most severe forms. Prior work in our laboratory has utilized a novel bioluminescent imaging (BLl) approach to understand the early events in GVHD pathophysiology whereby donor derived T cells migrate to secondary nodal sites and actively proliferate. In these tissues conventional CD4+ and CD8+ T (Tcon) cells up-regulate homing receptors that allow entry into GVHD target organs such as the skin, gastrointestinal tract, liver and immune tissues such as lymph nodes and the thymus. Controlling this robust Immunological reaction is difficult both in murine models and in patients. Recently we have discovered that immune regulatory T cells are capable of controlling GVHD pathophysiology without interfering with graft vs tumor (GVT) reactions and resulting in more effective immune reconstitution due to preservation of immune tissues required for effective immune reconstitution. We have studied both CD4+CD25+FoxP3+ regulatory T cells (Treg) and alpha/betaTCR+CD4+NK1.1+ natural killer T (NK-T) cells. Using BLl and other techniques we have observed that Treg control GVHD by inhibiting Tcon proliferation whereas NK-T cells function through an alternative mechanism. In this Project we will utilize novel animal models and TCR sequencing technologies to explore the biological basis of T cell activation in GVHD and GVT in Specific Aim #1.
In Specific Aim #2 we will compare the impact of Treg and NK-T cells on Tcon proliferation, phenotype and function.
Specific Aim #3 will translate these findings in a clinical trial of allogeneic HCT in patients with high risk malignancies who will receive a CD34+ cell selected graft followed by Treg and Tcon infusion in an effort to reduce GVHD while maintaining GVT and improving immune reconstitution.

Public Health Relevance

This project addresses the biological basis of GVHD induction by alloreactive T cells and the impact of regulatory T cell populations known to control this clinically relevant immune reaction. We hope to gain important biological insights into immune reactions including GVHD and GVT, as well as the function of regulatory T cell populations. Further, we will translate these findings to the clinic to improve upon allogeneic HCT by reducing GVHD risk, maintaining GVT and resulting in more effective immune reconstitution.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA049605-25
Application #
8744811
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
25
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Stanford University
Department
Type
DUNS #
City
Stanford
State
CA
Country
United States
Zip Code
94304
Zerboni, Leigh; Sung, Phillip; Sommer, Marvin et al. (2018) The C-terminus of varicella-zoster virus glycoprotein M contains trafficking motifs that mediate skin virulence in the SCID-human model of VZV pathogenesis. Virology 523:110-120
Muffly, Lori; Sheehan, Kevin; Armstrong, Randall et al. (2018) Infusion of donor-derived CD8+ memory T cells for relapse following allogeneic hematopoietic cell transplantation. Blood Adv 2:681-690
Tavallaee, Mahkam; Steiner, David F; Zehnder, James L et al. (2018) Coexistence of BRAF V600E and TERT Promoter Mutations in Low-grade Serous Carcinoma of Ovary Recurring as Carcinosarcoma in a Lymph Node: Report of a Case. Int J Gynecol Pathol :
Du, Jing; Paz, Katelyn; Thangavelu, Govindarajan et al. (2017) Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells. Blood 129:3121-3125
Spinner, Michael A; Fernández-Viña, Marcelo; Creary, Lisa E et al. (2017) HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity. Blood Adv 1:1347-1357
Costa, Helio A; Neal, Joel W; Bustamante, Carlos D et al. (2017) Identification of a Novel Somatic Mutation Leading to Allele Dropout for EGFR L858R Genotyping in Non-Small Cell Lung Cancer. Mol Diagn Ther 21:431-436
Chen, Yi-Bin; Efebera, Yvonne A; Johnston, Laura et al. (2017) Increased Foxp3+Helios+Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells. Biol Blood Marrow Transplant 23:625-634
Xu, Liwen; You, Xiaoqing; Zheng, PingPing et al. (2017) Methodologic Considerations in the Application of Next-Generation Sequencing of Human TRB Repertoires for Clinical Use. J Mol Diagn 19:72-83
Paul, Jed; Sahaf, Bita; Perloff, Spenser et al. (2016) High-throughput allogeneic antibody detection using protein microarrays. J Immunol Methods 432:57-64
Pierini, Antonio; Strober, William; Moffett, Caitlin et al. (2016) TNF-? priming enhances CD4+FoxP3+ regulatory T-cell suppressive function in murine GVHD prevention and treatment. Blood 128:866-71

Showing the most recent 10 out of 307 publications